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Introduction 38 
The introduction of high-sensitivity cardiac troponin testing into clinical practice has transformed the 39 
assessment of patients with suspected acute coronary syndrome in the Emergency Department.1 The 40 
majority of patients can be discharged using accelerated diagnostic pathways that do not require 41 
hospital admission for peak cardiac troponin testing.2 These pathways are not recommended for 42 
patients with ST-segment elevation on the electrocardiogram,3,4 but given interpretation is dependent 43 
on experience, there is a risk patients could be inappropriately assessed.   44 
Methods 45 
Between June 2013, and March 2016, consecutive patients with suspected acute coronary syndrome 46 
were recruited across ten hospitals in the High-STEACS cluster randomized controlled trial.5 High-47 
sensitivity cardiac troponin I was measured using the Abbott ARCHITECTSTAT assay (Abbott 48 
Laboratories, Abbott Park, IL), which has a limit of detection of 1.2 ng/L, and a 99th-centile upper 49 
reference limit of 34 ng/L in men and 16 ng/L in women. The index diagnosis was independently 50 
adjudicated by two physicians, on review of all clinical information, according to the Universal 51 
Definition of Myocardial Infarction.6 Patients with type 1 ST-segment elevation myocardial 52 
infarction (STEMI) were stratified according to cardiac troponin concentration at presentation using 53 
a validated risk-stratification threshold (5 ng/L),1 the sex-specific 99th-centile, and the European 54 
Society of Cardiology (ESC) 0/1 hour pathway rule-in threshold (52 ng/L).4 Posterior STEMI was 55 
defined as those with STEMI and an acute occlusion of the circumflex, obtuse marginal, or posterior 56 
left ventricular artery on angiography. Time from symptom onset was recorded prospectively by 57 
attending clinicians. Comparisons between groups were performed using the Chi-squared test for 58 
categorical variables, and an unpaired t-test or the Kruskal-Wallis test for continuous variables. 59 
Statistical analysis was performed using R (v.3.6.1, R Foundation). The trial was approved by our 60 
 3 
research ethics committee, and as randomisation was at the hospital-level, individual patient consent 61 
was not sought.5 62 
 63 
Results 64 
The trial enrolled 48,282 consecutive patients of whom 925 had an adjudicated diagnosis of STEMI 65 
(67.8% male, mean age 65 [SD 14] years). At presentation the median troponin concentration was 66 
196 ng/L (interquartile range [IQR] 46-21,611 ng/L), with 2.2% (20/925) and 14.4% (133/925) of 67 
patients having concentrations <5 ng/L and the 99th-centile, respectively (Figure). Just 73.2% 68 
(677/925) of patients had troponin concentrations above the rule-in threshold of 52 ng/L. Patients 69 
presenting within 2 hours of symptom onset (23.4%, 216/809) had lower troponin concentrations (96 70 
[26- 494] versus 294  [59-3042] ng/L; P<0.001), and were more likely to have concentrations below 71 
the 99th-centile (26.4%, (57/216) versus 14.1%, (95/674); P<0.001), compared to those presenting 72 
later. Posterior STEMI was more common in patients presenting with troponin below the 99th-centile 73 
(18.1%, (26/144) versus 9.8%, (61/618); P=0.008).  74 
 75 
Discussion 76 
Despite significant advances in the sensitivity of cardiac troponin testing, more than 1 in 4 patients 77 
with STEMI have troponin concentration below the ESC-recommended rule-in threshold at 78 
presentation. Patients presenting within 2 hours were more likely to have a troponin concentration 79 
below the 99th-centile, however even in those who presented later, 1 in 6 had troponin concentrations 80 
below the diagnostic threshold. During myocardial infarction, abrupt coronary occlusion may prevent 81 
the release of troponin into the circulation until reperfusion has occurred. Our observations are an 82 
important reminder of the limited role of troponin testing in the early assessment of patients with ST-83 
segment elevation. Where clinical suspicion is high, troponin concentrations within the reference 84 
range should not delay the initiation of therapeutic agents, or urgent coronary angiography. This is 85 
particularly relevant in patients with electrocardiographic changes suspicious of posterior myocardial 86 
 4 
infarction, but our findings are relevant to a wider group of patients with conduction abnormalities, 87 
such as bundle branch block or ventricular pacing, where interpretation of the electrocardiogram is 88 
challenging. 89 
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Figure.  159 
 160 
 161 
 162 
 163 
High-sensitivity cardiac troponin I concentrations in consecutive patients with ST-segment 164 
elevation myocardial infarction stratified by troponin concentration at presentation 165 
 166 
Patients were stratified by time of onset of symptoms (<2 hours, ≥2 hours) and according to cardiac 167 
troponin concentration at presentation. Individual patient concentrations (below the rule-out 168 
threshold of <5 ng/L (green), 5 ng/L to the 99th-centile diagnostic threshold (yellow), 99th-centile to 169 
52 ng/L rule-in threshold for the ESC 0/1 hours pathway (orange), and >52 ng/L (red)) are shown 170 
with box and whisker distribution and probability density plots. Peak concentration is the highest 171 
troponin concentration obtained on serial sampling.  172 
 173 
Abbreviations: hs-TnI, high-sensitivity cardiac troponin; ng/L, nanograms per liter 174 
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